A Lactobacillus plantarum HYZQF 1675-6 No. 2 and its application in preparing a product for preventing non-alcoholic fatty liver disease

The intestinal flora is regulated through Lactobacillus planta HYZQF 1675-6 2, providing key metabolites, solving the prevention and treatment problems of non-alcoholic fatty liver disease, significantly improving lipid and glucose metabolism, reducing liver steatosis and Inflammation has significant preventive effects.

CN118652825BActive Publication Date: 2024-11-01SHANDONG HUANYI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411154196.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-01
Estimated Expiration
2044-08-22

AI Technical Summary

Technical Problem

The incidence of non-alcoholic fatty liver disease continues to rise, and the prior art has failed to effectively prevent and treat the disease, especially the mechanisms related to the intestinal flora have not been fully utilized.

Method used

Provide a Lactobacillus plantarum HYZQF No. 1675-6 2 and its prepared microbial agent are prepared by freezing and lyophilization. It is used to prepare products for preventing non-alcoholic fatty liver disease, regulate the balance of intestinal microbial flora, and improve the color of intestinal tract. content of glycosides, chlorogenic acid, resveratrol, arbutin, catechin and beta-glucan.

Benefits of technology

Lactobacillus plantarum HYZQF No. 1675-6 2 can provide the above metabolites in intestinal reproduction, which have the effects of antioxidant, anti-inflammatory, insulin sensitization, lowering cholesterol, improving lipid and glucose metabolism, effectively preventing and reducing non-alcoholic Fatty liver disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention relates to the field of microbial technology, and in particular to a Lactobacillus plantarum HYZQF 1675-6 No. 2 and its application in preparing a product for preventing non-alcoholic fatty liver disease. Lactobacillus plantarum HYZQF 1675-6 No. 2 ( Lactobacillus plantarum HYZQF 1675‑6 No. 2), the results showed that Lactobacillus plantarum HYZQF 1675‑6 No. 2 can sustainably provide the necessary amount of anthocyanins, chlorogenic acid, resveratrol, arbutin, catechins and β‑glucan during intestinal reproduction and growth. Anthocyanins, chlorogenic acid, resveratrol, arbutin, catechins and β‑glucan can effectively prevent non-alcoholic fatty liver disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to Lactobacillus plantarum HYZQF 1675-6 2 and application thereof in preparing a product for preventing non-alcoholic fatty liver disease. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] With the development of human society and economy, people's diet and lifestyle have undergone tremendous changes. The prevalence of various metabolic diseases has increased year by year, and the resulting disease burden has also increased year by year. Nonalcoholic fatty liver disease (NAFLD), as a common metabolic disease, has become a chronic disease worthy of attention.

[0004] Nonalcoholic fatty liver disease is a disease caused by excessive fat accumulation in liver cells. In recent years, with the development of economy and the improvement of living standards, the incidence of nonalcoholic fatty liver disease has continued to rise worldwide, and now ranks first in the incidence of chronic liver diseases in the world. Although the pathogenesis of nonalcoholic fatty liver disease has not been fully elucidated, its pathogenesis is mainly related to metabolic abnormalities, such as insulin resistance (IR), type 2 diabetes, visceral obesity, abnormal blood lipid metabolism, etc.

[0005] With the introduction of the concept of "gut-liver axis", the relationship between the occurrence and development of non-alcoholic fatty liver disease and intestinal flora has gradually attracted attention. A large number of studies have shown that intestinal flora plays an important role in the occurrence, development and treatment of non-alcoholic fatty liver disease. Summary of the invention

[0006] In order to overcome the above problems, the present invention provides a Lactobacillus plantarum HYZQF 1675-6 2 and its application in preparing a product for preventing non-alcoholic fatty liver disease.

[0007] In order to achieve the above technical objectives, the present invention adopts the following technical solutions:

[0008] The first aspect of the present invention provides a Lactobacillus plantarum HYZQF 1675-6 2 (Lactobacillus plantarum HYZQF 1675-6 2), which is deposited in China Center for Type Culture Collection on March 22, 2019, and has a deposit number of CCTCC NO: M 2019191.

[0009] The second aspect of the present invention provides a microbial agent, wherein the microbial agent uses the bacterial liquid or bacterial powder of Lactobacillus plantarum HYZQF 1675-6 2 described in the first aspect as an active ingredient.

[0010] In one or more embodiments, the bacterial powder of Lactobacillus plantarum HYZQF 1675-6 2 is prepared by freezing and freeze-drying, and contains 1×10 7 ~1×10 14 / g of inactivated bacteria.

[0011] In one or more embodiments, the bacterial solution of Lactobacillus plantarum HYZQF 1675-6 No. 2 is obtained by diluting the freeze-dried bacterial powder of Lactobacillus plantarum HYZQF 1675-6 No. 2 with sterile physiological saline.

[0012] The third aspect of the present invention provides use of the Lactobacillus plantarum HYZQF 1675-6 No. 2 described in the first aspect and / or the microbial agent described in the second aspect in the preparation of a product for preventing non-alcoholic fatty liver disease.

[0013] In one or more embodiments, the products include drugs and pharmaceutical compositions.

[0014] The fourth aspect of the present invention provides use of the Lactobacillus plantarum HYZQF 1675-6 2 described in the first aspect and / or the microbial agent described in the second aspect in the preparation of a product for regulating the balance of intestinal microbial flora and promoting digestion.

[0015] In one or more embodiments, the products include drugs and pharmaceutical compositions.

[0016] The fifth aspect of the present invention provides the use of the Lactobacillus plantarum HYZQF 1675-6 No. 2 described in the first aspect and / or the microbial agent described in the second aspect in any of the following:

[0017] A1) Increase the content of anthocyanins during intestinal reproduction;

[0018] A2) Preparation of products for increasing anthocyanin content in intestinal reproduction processes;

[0019] A3) Increase the content of chlorogenic acid during intestinal reproduction;

[0020] A4) Preparation of products for increasing the content of chlorogenic acid in intestinal reproduction;

[0021] A5) Increase the content of resveratrol in the intestinal reproduction process;

[0022] A6) preparing products for increasing resveratrol content in intestinal reproduction;

[0023] A7) Increase the content of arbutin during intestinal reproduction;

[0024] A8) Preparation of products for increasing the content of arbutin in intestinal reproduction;

[0025] A9) Increase the content of catechins during intestinal reproduction;

[0026] A10) Preparation of products for increasing the catechin content in intestinal reproduction;

[0027] A11) Increase the content of β-glucan during intestinal reproduction;

[0028] A12) Preparation of products for increasing the beta-glucan content in intestinal reproduction processes.

[0029] In one or more embodiments, the products include drugs and pharmaceutical compositions.

[0030] The beneficial effects of the present invention are:

[0031] Based on the isolation of Lactobacillus plantarum HYZQF 1675-6 No. 2 from fresh blueberry pulp, the results showed that Lactobacillus plantarum HYZQF 1675-6 No. 2 can sustainably provide the necessary amount of endogenous anthocyanins, chlorogenic acid, resveratrol, arbutin, catechins and β-glucan during intestinal reproduction and growth. Among them, anthocyanins play an important preventive role in non-alcoholic fatty liver disease by balancing lipid storage and metabolism of non-alcoholic fatty liver disease, regulating redox stress, intestinal flora, transcription factors, sugar metabolism and inflammation. Chlorogenic acid itself has strong antioxidant activity, anti-inflammatory effect, antibacterial activity and insulin sensitization properties; in addition, it can improve lipid and glucose metabolism by promoting the removal of triglycerides and free fatty acids and improving insulin sensitivity; chlorogenic acid has the effect of lowering cholesterol and can reduce oxidative stress caused by a high-fat diet; it can relieve liver fatty degeneration and inhibit fatty acid synthesis. Resveratrol can prevent non-alcoholic fatty liver disease by anti-inflammation, regulating autophagy, improving mitochondrial function, and regulating liver lipid metabolism. Arbutin can not only regulate oxidative stress and lipid metabolism to prevent obesity-related non-alcoholic fatty liver disease, but also inhibit ferroptosis to prevent non-alcoholic fatty liver disease. Catechins can help prevent non-alcoholic fatty liver disease by reducing liver damage markers, regulating lipid and carbohydrate metabolism, reducing inflammation and oxidative stress, and reducing liver cell damage. β-Glucan is a dietary fiber with low triglyceride and anti-inflammatory properties. It can regulate liver lipid metabolism and prevent non-alcoholic fatty liver disease. In addition, β-Glucan can be used as the main carbon source for fermentation of Bifidobacterium longum subspecies, increasing the abundance of probiotics and is beneficial to the prevention of non-alcoholic fatty liver disease. DETAILED DESCRIPTION

[0032] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0033] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0034] The Lactobacillus plantarum HYZQF 1675-6 2 provided in the present invention is deposited in the China Center for Type Culture Collection on March 22, 2019, and the deposit number is CCTCC NO: M 2019191.

[0035] The bacterium was isolated by Cao Chongren from fresh blueberry pulp in Yichun City, Heilongjiang Province in October 1995 and was identified as Lactobacillus plantarum by 16srRNA method. The nucleotide sequence of Lactobacillus plantarum HYZQF 1675-6 2 is shown in SEQ ID NO.1.

[0036] The nucleotide sequence shown in SEQ ID NO.1 is as follows:

[0037]

[0038] Example 1

[0039] Preparation of freeze-dried powder of inactivated bacterial metabolites of Lactobacillus plantarum HYZQF 1675-6 No. 2:

[0040] (1) Bacteria activation

[0041] Bacterial strain culture: Expansion culture of bacterial strains preserved in -80℃ refrigerator.

[0042] Preparation of culture medium: 10 g galacto-oligosaccharide, 5 g raffinose, 3 g maltitol, 3 g beef extract powder, 2 g sodium acetate, 0.5 mL Tween-80, 0.4 g potassium dihydrogen phosphate, 1000 mL tap water, pH adjusted to 7.0 (adjusted with alkali solution).

[0043] Operation: Add the galacto-oligosaccharide and other raw materials in the above formula into 1000 mL of water in the formula without any particular order, stir for 10 min to dissolve, and then divide into test tubes, each test tube contains 5.0 mL, seal with kraft paper and put in a medical sterilizer for sterilization at 0.1-0.12 MPa for 20 min. The culture medium is ready.

[0044] Inoculation: Under sterile conditions (clean bench), open the -80 ℃ low-temperature refrigerator to store the frozen tube of bacteria, and melt it at room temperature. Then take one sterilized test tube culture medium, add 0.5 mL of the dissolved bacterial solution into the test tube, seal the tube mouth with kraft paper, shake it gently by hand, and place it in a constant temperature incubator at 37 ℃ for 16 hours. This is called expansion culture medium.

[0045] (2) Preparation of primary bacterial culture liquid:

[0046] Primary seed culture formula: 5 g isomaltulose, 3 g peptone, 2 g beef extract powder, 1.2 g arginine, 0.5 g sodium acetate, 1.5 g threonine, 0.3 g tyrosine, 1 mL Tween-80, 1000 mL tap water, natural pH.

[0047] Operation: Add the above raw materials into 1000 mL of tap water without any distinction, start the blender, and stir for 10 minutes to dissolve them all. This is called the primary seed culture solution.

[0048] Add the stirred and dissolved first-level seed culture solution into the conical flask according to the dosage, then wrap the bottle mouth with 6 layers of gauze and one layer of kraft paper, and put it into the sterilizer for sterilization. Before sterilization, first open the exhaust valve on the sterilizer and close it when a small amount of steam is discharged. When the pressure on the sterilizer reaches 0.05 MPa, open the exhaust valve on the sterilizer to exhaust for 6~8 minutes, then close the exhaust valve and continue heating. When the steam pressure in the sterilizer reaches 0.1~0.12MPa, start timing. The sterilization time is 20 min. After completion, leave the heat source and let it cool down naturally. When the pressure gauge on the sterilizer returns to zero, open the sterilizer, take out the sterilized culture medium and put it into the clean bench for natural cooling. When the temperature drops to 37 ℃, transfer the above cultured expansion culture solution to the conical flask containing the sterilized culture solution. The inoculation amount is 0.5%, that is, 100 mL of first-level seed culture solution and 0.5 mL of expansion culture solution. mL. After completion, seal the bottle mouth with the original gauze and kraft paper, shake it slightly by hand to mix the inoculated bacteria and culture solution evenly, and then place it in a constant temperature box and culture it at 37 ℃ for 18 h. This is called the primary culture solution.

[0049] (3) Preparation of seed tank strains:

[0050] Sterilization of fermentation equipment, pipelines and sterile filtration systems:

[0051] First, open the valves of all inlet and outlet pipelines and sterile air pipelines, and pass 0.12~0.14 MPa steam. Allow the steam to connect with the pipeline valves and discharge a small amount of steam. Ventilate for 40 minutes, then close the valves of all inlet and outlet pipelines and set aside.

[0052] Sterilization of empty seed tanks and fermentation tanks:

[0053] Close all valves, open the drain valve at the bottom of the tank and the drain valve in the tank interlayer, open the direct steam valve to introduce 0.12~0.14 MPa steam into the pipe, start timing when the temperature in the tank reaches 121 ℃, the sterilization time is 40 min, then close the drain valve at the bottom of the tank and the drain valve in the interlayer, and the temperature in the tank will naturally drop to 37 ℃ for standby use.

[0054] Seed pot culture:

[0055] Formula: 1% glucose, 1% raffinose, 2% isomaltulose, 0.9% casein peptone, 0.3% dipotassium hydrogen phosphate, 0.8% proline, 0.7% sodium acetate, 1.1% arginine, 0.1% Tween-80, 0.1% polyether defoamer, 92% tap water, natural pH.

[0056] Specific operation: First, pour the tap water used in the formula into the sterilized seed tank, start the mixer, add the raw materials required in the formula respectively (the order of addition does not matter), then stir continuously and pass steam for heating. First, use the steam in the tank interlayer to heat to 95°C, then switch to direct steam heating. When the temperature in the tank reaches 121°C, maintain it for 20 minutes to achieve the sterilization effect, then turn off the steam, and start cooling through the tap water in the tank interlayer. When the temperature in the tank reaches 37°C, it is ready for use. This is called seed culture medium. Then inoculate the above-cultured first-level bacterial culture solution into the seed tank under sterile conditions. The inoculation amount is 3% of the culture medium in the tank. 100 kg of seed tank culture medium can be inoculated with 3 kg of first-level bacterial solution. Then cover the inoculation cap on the tank and start stirring and culturing. The culture conditions are: temperature 37 °C, natural pH value, stirring speed 140 r / min, tank pressure 0.05 MPa, and culture time 12 h to meet the requirements. If the tank body is lowered, sterile air can be introduced to maintain the tank pressure. If the tank pressure is too high, the air release valve on the tank top can be used to adjust it. This is called seed tank culture.

[0057] (4) Fermentation

[0058] Formula: 2% galacto-oligosaccharide, 0.5% glucose, 1% fructo-oligosaccharide, 1% casein peptone, 2% yeast peptone, 2.5% yeast extract powder, 1.3% sodium acetate, 0.2% Tween-80, 0.7% leucine, 0.9% dipotassium hydrogen phosphate, 0.1% polyether defoamer, and 87.8% tap water.

[0059] Specific operation: First, add the tap water used in the formula into the sterilized fermentation tank, start the mixer, add the raw materials used in the formula into the fermentation tank (the order of addition is not important), and then pass steam for heating. First, use the interlayer steam to heat to 95 ℃, and then switch to direct steam heating. When the temperature in the tank reaches 121 ℃, start timing, and keep it for 30 minutes to achieve the sterilization effect, and then cool it down with the interlayer tap water. When the temperature in the tank drops to 37 ℃, start to inoculate the strain. Before inoculation, first increase the tank pressure of the seed tank to 0.1 MPa, and keep the tank pressure of the fermentation tank at 0.05 MPa, then open the inoculation pipeline valve, and transport the seeds cultured in the seed tank to the fermentation tank by pressure difference, and then close the inoculation channel valve.

[0060] The inoculation amount is 3 kg of bacteria cultured in the seed tank for every 100 kg of culture medium in the fermentation tank. The culture conditions are: 0-5h culture temperature 37 °C, stirring speed 90 r / min, tank pressure maintained at 0.05 MPa, and the acid and alkali automatic control system is used to maintain the pH value at 6.5 during the fermentation process. If the tank pressure drops, sterile air can be introduced to maintain the tank pressure until the fermentation is completed. The total fermentation time is 30 hours, and then the temperature is lowered to 20 °C. This is the fermentation broth. 2% trehalose is added to the fermentation broth and kept at 120 °C for 5 seconds for UHT inactivation treatment.

[0061] (5) Centrifugation of fermentation broth

[0062] The fermentation liquid is pumped into a storage tank for centrifugation. Operation: Start the centrifuge, adjust the speed to 10000 r / min, centrifuge at a feed rate of 6 kg / min, collect the inactivated wet bacterial sludge metabolites after centrifugation, and freeze-dry the collected inactivated wet bacterial sludge metabolites.

[0063] (6) Freeze-drying of bacterial sludge metabolites

[0064] Preparation of bacterial suspension: Take 1000 g of inactivated wet bacterial sludge metabolites, add 4000 mL of sterile saline, 150 g of maltodextrin, 300 g of resistant dextrin, 1400 g of galacto-oligosaccharide, and 30 g of fucoidan.

[0065] Operation: First, take 2500 mL of sterile saline in the formula, add maltodextrin and stir to dissolve, then add 1000 g of inactivated wet bacterial sludge metabolites, and then add the remaining sterile saline and oligosaccharides and auxiliary materials in the formula and stir well, which is called a suspension. The suspension is freeze-dried and the moisture content is finally controlled to 4%, which becomes a freeze-dried powder of inactivated bacterial metabolites.

[0066] After testing, the freeze-dried powder obtained in Example 1 had a content of inactivated bacteria of 160 billion cells / g.

[0067] Example 2

[0068] Metabolomics analysis of mouse feces was performed using ultra-performance liquid chromatography-tandem mass spectrometry (LC-MS).

[0069] Experimental plan: The mice were divided into a control group and an experimental group. The control group was fed with normal food, while the experimental group was fed with food supplemented with 7×10 8The probiotic product containing inactivated bacterial cells and metabolites (freeze-dried powder obtained in Example 1) was fed for 30 days, 60 days, and 90 days. The fecal samples of the mice in the control group and the experimental group were placed in 400 μL of extraction solution (acetonitrile: methanol = 1: 1), vortexed for 30 s, and then subjected to low-temperature ultrasonic extraction for 30 min (5 ℃, 40 KHz), allowed to stand for 30 min at -20 ℃, placed in a 4 ℃ centrifuge, centrifuged at 13000 r / min for 15 min, and the supernatant was taken, dried with nitrogen, and re-dissolved with 120 μL of re-solution (acetonitrile: water = 1: 1), subjected to low-temperature ultrasonic extraction for 5 min (5 ℃, 40 KHz), placed in a 4 ℃ centrifuge, centrifuged at 13000 r / min for 5 min, and an appropriate amount of supernatant was taken for analysis. 10 μL of the sample supernatant was separated by a BEH C18 column (100 mm×2.1 mm id, 1.8 μm) and entered the mass spectrometry detection. The separation flow rate was 0.40 mL / min and the column temperature was 40 °C. After completion, the LC-MS raw data was transferred to the computer for processing and analysis. The mass spectrum information was matched with the public database, and the main metabolite information was obtained as shown in Table 1.

[0070] Table 1 Information of main metabolites

[0071]

[0072] The results showed that Lactobacillus plantarum HYZQF 1675-6 No. 2 can sustainably provide an endogenous amount of anthocyanins, chlorogenic acid, resveratrol, arbutin, catechins and β-glucan during intestinal reproduction and growth. Among them, anthocyanins play an important preventive role in non-alcoholic fatty liver disease by balancing lipid storage and metabolism, regulating redox stress, intestinal flora, transcription factors, sugar metabolism and inflammation. Chlorogenic acid itself has strong antioxidant activity, anti-inflammatory effect, antibacterial activity and insulin sensitization properties; in addition, it can improve lipid and glucose metabolism by promoting the removal of triglycerides and free fatty acids and improving insulin sensitivity; chlorogenic acid has the effect of lowering cholesterol and can reduce oxidative stress caused by a high-fat diet; it can relieve liver fatty degeneration and inhibit fatty acid synthesis. Resveratrol can prevent non-alcoholic fatty liver disease by anti-inflammation, regulating autophagy, improving mitochondrial function, and regulating liver lipid metabolism. Arbutin can not only regulate oxidative stress and lipid metabolism to prevent obesity-induced non-alcoholic fatty liver disease, but also inhibit ferroptosis to prevent non-alcoholic fatty liver disease. Catechins can help prevent non-alcoholic fatty liver disease by reducing liver damage markers, regulating lipid and carbohydrate metabolism, reducing inflammation and oxidative stress, and reducing liver cell damage. β-Glucan is a dietary fiber with low triglyceride and anti-inflammatory properties, which can regulate liver lipid metabolism and prevent non-alcoholic fatty liver disease; in addition, β-Glucan can be used as the main carbon source for fermentation of Bifidobacterium longum subspecies, increasing the abundance of probiotics and is beneficial to the prevention of non-alcoholic fatty liver disease.

[0073] Example 3

[0074] Forty male SD rats were selected and divided into a control group and an experimental group. The control group consisted of 10 rats, and the experimental groups were divided into experimental group 1, experimental group 2, and experimental group 3. The control group was fed with a high-sugar and high-fat diet, and the experimental group was fed with 7×10 8 The probiotic products of inactivated bacterial cells and metabolites (lyophilized powder obtained in Example 1) were fed to the mice for 19 weeks, and blood was taken for liver function test. The results of the test results of alanine aminotransferase (ALT / GPT) and aspartate aminotransferase (AST / GPT) levels in mouse serum are shown in Table 2.

[0075] Table 2 Results of serum ALT and AST concentrations (X̄±S)

[0076]

[0077] It can be seen from Table 2 that the Lactobacillus plantarum HYZQF 1675-6 No. 2 product prepared in Example 2 can improve the levels of alanine aminotransferase (ALT / GPT) and aspartate aminotransferase (AST / GPT) in mouse serum, and can prevent the occurrence of non-alcoholic fatty liver disease in a dose-dependent manner.

[0078] Example 4

[0079] (1) Experiment on regulating the function of mouse intestinal flora: The mice were divided into a control group and an experimental group, with 10 mice in each group. The control group was fed normal food, while the experimental group was fed with 7×10 8 The probiotic product of inactivated bacterial cells and metabolites (lyophilized powder obtained in Example 1) was obtained. Mouse feces were aseptically taken, weighed, diluted 10 times with a sterile diluent to make a uniform suspension, and then diluted 10 times in sequence, and the appropriate dilution was selected and inoculated on each selective culture medium. The number of bacteria per gram of wet feces was calculated, and the logarithm was taken for statistical processing. 24 hours after the last administration of the probiotic product, rectal feces were taken, and the intestinal flora was detected as shown in Table 3.

[0080] Table 3 Suitable culture conditions and detection of intestinal flora (X̄±SD)

[0081]

[0082] According to Table 3, probiotic products can increase the number of beneficial bacteria (Bifidobacterium and Lactobacillus), while the number of harmful bacteria (Enterobacter and Enterococcus) did not increase but showed a slight downward trend, indicating that probiotics can regulate the function of the intestinal flora in mice.

[0083] (2) Gastrointestinal motility experiment in mice: The mice were divided into control group, model group and experimental group, with 10 mice in each group. The control group and model group were given distilled water by gavage, and the experimental group was given probiotic products containing inactivated bacteria and metabolites by gavage. After gavage for 15 days, the mice in each group were fasted for 16 hours. Then the model group and experimental group were given compound difenocolone by gavage, and the control group was given distilled water by gavage. 30 minutes later, the mice in each group were given Arabic gum ink by gavage. After 30 minutes, the mice were killed by cervical vertebral dissection. After cervical vertebral dissection, the abdomen was quickly cut open along the midline of the abdomen to separate the mesentery, and the intestinal tube was cut with the pylorus as the starting point and the ileocecal part as the end point. The small intestine was gently pulled into a straight line, and the intestinal tube length was measured as the "total length of the small intestine", and the length from the pylorus to the front of the ink was the "ink propulsion length". The ink propulsion rate was calculated according to the following formula. The ink propulsion rate of the small intestine is shown in Table 4.

[0084]

[0085] Table 4 Small intestinal ink propulsion rate (X̄±SD)

[0086]

[0087] As shown in Table 4, the intestinal motility inhibition model of mice was established by administering compound difenocool. Compared with the model group, the small intestinal ink propulsion rate of the experimental group increased, indicating that probiotic products can promote small intestinal digestion.

[0088] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A Lactobacillus plantarum ( Lactobacillus plantarum ) HYZQF 1675-6 2, deposited in China Center for Type Culture Collection, the deposit date is March 22, 2019, and the deposit number is CCTCC NO: M 2019191.

2. A microbial agent, It is characterized in that The microbial agent uses the bacterial liquid or powder of Lactobacillus plantarum HYZQF 1675-6 2 as claimed in claim 1 as an active ingredient.

3. The microbial agent according to claim 2, It is characterized in that The powder of Lactobacillus plantarum HYZQF 1675-6 No. 2 was prepared by freezing and freeze-drying, containing 1×10 7 ~1×10 14 / g of inactivated bacteria.

4. The microbial agent according to claim 2, It is characterized in that The bacterial liquid of Lactobacillus plantarum HYZQF 1675-6 No. 2 is obtained by diluting the freeze-dried bacterial powder of Lactobacillus plantarum HYZQF 1675-6 No. 2 with sterile saline.

5. Use of the plant lactobacillus HYZQF 1675-6 2 according to claim 1 and / or the microbial agent according to any one of claims 2 to 4 in the preparation of a product for preventing non-alcoholic fatty liver disease.

6. The use according to claim 5, It is characterized in that The products include drugs and pharmaceutical compositions.

7. Use of the plant lactobacillus HYZQF 1675-6 2 according to claim 1 and / or the microbial agent according to any one of claims 2 to 4 in the preparation of products for regulating the balance of intestinal microbial flora and promoting digestion.

8. The use according to claim 7, It is characterized in that The product includes any one of medicines and pharmaceutical compositions, health products, foods or food additives, and feeds or feed additives.